Atrayee Basu Mallick
Overview
Explore the profile of Atrayee Basu Mallick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Islam R, Roche M, Lin Z, Whitaker-Menezes D, Diaz-Barros V, Serrano E, et al.
Mol Oncol
. 2025 Feb;
PMID: 39996379
Chondrosarcomas are common bone sarcomas frequently resistant to radiation and chemotherapy, with high recurrence rates, development of metastatic disease, and death. Fibrosarcomas are soft tissue sarcomas associated with poor outcomes....
2.
Wei S, Patchefsky A, Pei J, Brown S, Basu Mallick A, Wang Z, et al.
Am J Clin Pathol
. 2024 Sep;
163(2):224-230.
PMID: 39250713
Objectives: Ossifying fibromyxoid tumor (OFMT) is a rare soft tissue neoplasm of uncertain histogenesis. Most OFMTs have benign behavior, and many harbor gene fusions involving the PHD finger protein 1...
3.
Poiset S, Shah S, Cappelli L, Anne P, Mooney K, Werner-Wasik M, et al.
Radiat Oncol
. 2024 May;
19(1):65.
PMID: 38812040
Background: Local treatment options for locally recurrent pancreatic adenocarcinoma (LR-PAC) are limited, with median survival time (MST) of 9-13 months (mos) following recurrence. MRI-guided stereotactic body radiation therapy (MRgSBRT) provides...
4.
Micaily I, Blais E, Carhart R, Lam S, Cohen S, Cannaday S, et al.
JCO Precis Oncol
. 2023 Dec;
7:e2200648.
PMID: 38085059
Purpose: Pancreatic adenocarcinoma is an aggressive disease with poor clinical outcomes. Primary pancreatic tumors originating from the head of the pancreas (H) have different prognostic implications than tumors arising from...
5.
Robbins J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, Ganetzky R, Lavu H, et al.
N Engl J Med
. 2023 Nov;
389(21):1972-1978.
PMID: 37991855
Mahvash disease is an exceedingly rare genetic disorder of glucagon signaling characterized by hyperglucagonemia, hyperaminoacidemia, and pancreatic α-cell hyperplasia. Although there is no known definitive treatment, octreotide has been used...
6.
Gomaa S, Posey J, Bashir B, Basu Mallick A, Vanderklok E, Schnoll M, et al.
JMIR Form Res
. 2023 Nov;
7:e46128.
PMID: 37948108
Background: Outpatient chemotherapy often leaves patients to grapple with a range of complex side effects at home. Leveraging tailored evidence-based content to monitor and manage these symptoms remains an untapped...
7.
Lin R, Basu Mallick A, Wang Z, Brown S, Lu B, Jiang W
Diagn Pathol
. 2023 Oct;
18(1):116.
PMID: 37865792
Background: Among the three NTRK genes, NTRK2 possesses a tremendous structural complexity and involves tumorigenesis of several types of tumors. To date, only STRN and RBPMS are identified in the...
8.
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas
Kummar S, Shen L, Hong D, McDermott R, Keedy V, Casanova M, et al.
Cancer
. 2023 Sep;
129(23):3772-3782.
PMID: 37769113
Background: Larotrectinib, a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor, has demonstrated efficacy in adult and pediatric patients with various solid tumors harboring NTRK gene fusions. This subset analysis...
9.
Meredith L, Chao T, Nevler A, Basu Mallick A, Singla R, McCue P, et al.
Diagn Pathol
. 2023 Apr;
18(1):45.
PMID: 37041531
Background: Malignant perivascular epithelioid cell tumors (PEComas) are exceedingly rare malignant mesenchymal neoplasms with characteristic morphological and immunohistochemical (IHC) patterns. However, some malignant PEComas are poorly differentiated with atypical histopathological...
10.
Scott A, Basu Mallick A, Dotan E, Cohen S, Gold P, Hochster H, et al.
Cancer Res Commun
. 2023 Mar;
2(10):1188-1196.
PMID: 36969746
Purpose: Multi-tyrosine kinase inhibitors (TKI) have shown clinical activity in patients with metastatic colorectal cancer. Cabozantinib, a multi-TKI, exhibited potent antitumor activity superior to regorafenib in preclinical colorectal cancer patient-derived...